Form 4: Dianthus Therapeutics Director Receives Stock Option Grant

Director Simon Read was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity compensation award.

Summary

• Director Simon Read received a grant of 6,090 stock options on May 21, 2026.
• The options have an exercise price of $89.63 per share.
• The options are set to expire on May 21, 2036.
• The award vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the issuer.

Future Outlook

The options vest in full on the earlier of May 21, 2027, or the date of the 2027 Annual Meeting of Stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align governance with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is a common retention mechanism for board members.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on the earlier of May 21, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Form 4, Insider Trading, Stock Options, Equity Compensation